Low‐risk gestational trophoblastic neoplasia – 20 years experience of a state registry
Australian and New Zealand Journal of Obstetrics and Gynaecology · 2024
DOI: 10.1111/ajo.13772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2024. Verfasst von Carmel McInerney und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecological Oncology, The Royal Women's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Gestational Trophoblastic Disease, Registries, Methotrexate. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Gestational trophoblastic disease (GTD) is an uncommon but highly treatable condition. There is limited local evidence to guide therapy.
Aims
To report the experience of a statewide registry in the treatment of low‐risk gestational trophoblastic neoplasia (GTN) over a 20‐year period. Materials and Methods A retrospective review of the prospectively maintained GTD registry database was conducted. There were 144 patients identified with low‐risk GTN, of which 115 were analysed. Patient demographics, treatment details and outcomes, including development of resistance, toxicity or relapse were reviewed.
Results
The incidence of GTD was 2.6/1000 live births. There was 100% survival. The mean time from diagnosis to commencing treatment was 1.9 days (range 0–29 days). Seventy‐seven percent of patients treated with methotrexate achieved complete response. Thirteen patients (11.3%) required multi‐agent chemotherapy, for the treatment of resistant or relapsed disease. There was a higher rate of treatment resistance in those with World Health Organization (WHO) risk scores 5–6 (odds ratio (OR) 6.56, 95% CI 1.73–24.27, P = 0.005) and those with pre‐treatment human chorionic gonadotropin >10 000 (OR 4.00 95% CI 1.73–24.27 P = 0.007). Four patients (3.5%) were diagnosed with choriocarcinoma after commencing treatment. Nine patients (7.8%) had successful surgical treatment for GTN, both alone and in combination with chemotherapy. The relapse rate was 4.3%; all were treated successfully with a combination of chemotherapy and surgery, and 93.9% of patients completed follow up through the registry.
Conclusions
Methotrexate is a highly effective treatment for low‐risk GTN, especially with WHO risk score ≤ 4. The optimal treatment for those with risk scores of 5–6 requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecological Oncology, The Royal Women's Hospital, Melbourne, Victoria, Australia.
- Department of Obstetrics and Gynaecology, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Obstetrics and Gynaecology, The Royal Women's Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Carmel McInerney
Zitieren
APA
McInerney, C., McNally, O., Cade, T. J., Jones, A., Neesham, D., & Naaman, Y. (2024). Low‐risk gestational trophoblastic neoplasia – 20 years experience of a state registry. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.13772
Vancouver
McInerney C, McNally O, Cade TJ, Jones A, Neesham D, Naaman Y. Low‐risk gestational trophoblastic neoplasia – 20 years experience of a state registry. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2024. doi:10.1111/ajo.13772
BibTeX
@article{McInerney2024,
author = {McInerney, Carmel and McNally, Orla and Cade, Thomas James and Jones, Antonia and Neesham, Deborah and Naaman, Yael},
title = {Low‐risk gestational trophoblastic neoplasia – 20 years experience of a state registry},
journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
year = {2024},
doi = {10.1111/ajo.13772}
}
EUVIMED